Semaphorin 3A and 3F Promote Lumen Expansion in TIE2-Mutated Venous Malformation
Arteriosclerosis, Thrombosis, and Vascular Biology · 2025-12 · 45 (12) · 2243-2260
DOI: 10.1161/atvbaha.125.323387 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2025-12. Verfasst von Sandra Schrenk und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, OH (S.S., C.S., L.J.B., Y.C., E.B.). Hauptthemen laut MEDLINE: Receptor, TIE-2, Vascular Malformations, Mutation, Endothelial Cells. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Venous malformations (VMs) are developmental defects of the vasculature characterized by tremendously enlarged and dysfunctional veins. Gain-of-function somatic mutations in TIE2 (endothelial tyrosine kinase receptor) have been identified as the leading driver of VM pathogenesis. The aim of this study was to determine whether the aberrant venous lumen expansion is caused by recruitment of wild-type (WT) endothelial cells (EC) to the lesion or by TIE2-mutant EC clonal expansion. METHODS: To investigate the contribution of TIE2-mutant EC and WT EC to the aberrant venous lumen expansion, we used a xenograft murine model of VM generated with a combination of TIE2-mutant EC and WT EC. To perform longitudinal studies, we used a 3-dimensional fibrin gel lumen formation assay and a migration assay, both using WT EC in competition or confrontation with TIE2-mutant EC. To investigate the mechanisms implicated in VM lumen expansion, we used RNA-sequencing and short-hairpin RNA silencing in the TIE2-mutant EC. RESULTS: We demonstrate here that in the VM xenograft model, the aberrant blood vessels were lined almost exclusively by TIE2-mutant EC, and WT EC were rarely found. Functionally, the TIE2-mutant EC exerted a competitive advantage over WT EC by inhibiting WT EC sprouting. In line with these findings, TIE2-mutant EC promoted repulsion of WT EC. Short-hairpin RNA-mediated silencing of Sema (Semaphorin) 3A or Sema3F in TIE2-mutant EC rescued this chemorepellent phenotype and restored the ability of WT EC to migrate, sprout, and form lumens. Furthermore, knockdown of Sema3A or Sema3F in TIE2-mutant EC normalized the blood vessel size in vivo. CONCLUSIONS: Our results demonstrate that WT EC are not recruited to the aberrant veins, suggesting that VM pathogenesis is fueled by clonal expansion of TIE2-mutant EC. Mechanistically, we show that Sema3A and Sema3F are overexpressed in TIE2-mutant EC and play a crucial role in the pathological vascular lumen expansion in VM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, OH (S.S., C.S., L.J.B., Y.C., E.B.).
- Department of Pediatrics (S.S., E.B.), University of Cincinnati College of Medicine, OH.
- Department of Cancer Biology (L.J.B.), University of Cincinnati College of Medicine, OH.
ORCID-Profile: Sandra Schrenk, Chhiring Sherpa, Lindsay J Bischoff, Yuqi Cai, Elisa Boscolo
Förderung
- NHLBI NIH HHS
Zitieren
APA
Schrenk, S., Sherpa, C., Bischoff, L. J., Cai, Y., & Boscolo, E. (2025). Semaphorin 3A and 3F Promote Lumen Expansion in TIE2-Mutated Venous Malformation. Arteriosclerosis, Thrombosis, and Vascular Biology, 45(12), 2243-2260. https://doi.org/10.1161/atvbaha.125.323387
Vancouver
Schrenk S, Sherpa C, Bischoff LJ, Cai Y, Boscolo E. Semaphorin 3A and 3F Promote Lumen Expansion in TIE2-Mutated Venous Malformation. Arteriosclerosis, Thrombosis, and Vascular Biology. 2025;45(12):2243-2260. doi:10.1161/atvbaha.125.323387
BibTeX
@article{Schrenk2025,
author = {Schrenk, Sandra and Sherpa, Chhiring and Bischoff, Lindsay J and Cai, Yuqi and Boscolo, Elisa},
title = {Semaphorin 3A and 3F Promote Lumen Expansion in TIE2-Mutated Venous Malformation},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2025},
volume = {45},
number = {12},
pages = {2243--2260},
doi = {10.1161/atvbaha.125.323387}
}
EUVIMED